CD4 and myopathy: In this line, a previous study of inflammatory myopathies in patients evidenced the crucial role of ICOSL in inducing CD4+ T-cell responses (both Th1 and Th2), which could be suppressed in vitro by using an anti-ICOSL antibody (45).